Methotrexate Teva (Methotrexate Sodium)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a key cofactor for DNA and RNA synthesis. This interruption hampers the replication of rapidly dividing cells, such as immune cells in arthritis and cancer cells in leukemia or lymphoma.

The specific dose and schedule of Methotrexate Teva are determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage may vary widely between rheumatologic and oncologic indications.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Methotrexate is the most widely used folate antagonist and offers a broad therapeutic range across autoimmune and oncologic diseases. Compared with newer agents, it is generally less expensive but requires careful monitoring for hepatic, renal and hematologic toxicity. Choice of therapy depends on disease severity, patient comorbidities and clinician experience.

Methotrexate Teva should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight and extreme heat to maintain product stability.

The product is supplied as a sterile solution for parenteral routes such as epidural, intrabursal or intracoronary injection. Administration is performed by qualified healthcare professionals following aseptic technique and the dosing instructions provided by the prescriber.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to infection or bleeding, acute renal failure, and life‑threatening allergic reactions. Patients should be monitored regularly for signs of organ dysfunction and instructed to report any unusual symptoms promptly.

Methotrexate Teva is contraindicated in pregnant women, breastfeeding mothers, patients with severe hepatic or renal impairment, and individuals with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with active infections or immunodeficiency.